RAPT Therapeutics (RAPT) Cash & Current Investments (2020 - 2024)
Historic Cash & Current Investments for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $97.9 million.
- Therapeutics' Cash & Current Investments fell 4701.45% to $97.9 million in Q3 2024 from the same period last year, while for Sep 2024 it was $97.9 million, marking a year-over-year decrease of 4701.45%. This contributed to the annual value of $158.9 million for FY2023, which is 3621.74% down from last year.
- According to the latest figures from Q3 2024, Therapeutics' Cash & Current Investments is $97.9 million, which was down 4701.45% from $114.8 million recorded in Q2 2024.
- In the past 5 years, Therapeutics' Cash & Current Investments registered a high of $249.1 million during Q4 2022, and its lowest value of $97.9 million during Q3 2024.
- Moreover, its 5-year median value for Cash & Current Investments was $173.0 million (2022), whereas its average is $167.7 million.
- In the last 5 years, Therapeutics' Cash & Current Investments soared by 7581.04% in 2022 and then tumbled by 4701.45% in 2024.
- Over the past 5 years, Therapeutics' Cash & Current Investments (Quarter) stood at $111.5 million in 2020, then skyrocketed by 70.08% to $189.7 million in 2021, then surged by 31.33% to $249.1 million in 2022, then tumbled by 36.22% to $158.9 million in 2023, then crashed by 38.37% to $97.9 million in 2024.
- Its Cash & Current Investments stands at $97.9 million for Q3 2024, versus $114.8 million for Q2 2024 and $141.6 million for Q1 2024.